



## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. PC9517H

SERIAL NO. 10/615,282

APPLICANT David B. MacLean, et al.


FILING DATE 7/7/2003

GROUP 1614

## U.S. PATENT DOCUMENTS

ce	US	3	2	3	4	0	9	0	2/8/66	Charles F. Huebner	167	58	
f	US	3	2	7	4	2	1	3	9/20/66	Daniel Lednicer	260	326.5	
	US	3	2	7	7	1	0	6	10/4/66	William L. Bencze	260	295	
	US	3	2	9	3	2	6	3	12/20/66	Daniel Lednicer	260	326.5	
	US	3	3	2	0	2	7	1	5/16/67	Daniel Lednicer	260	307	
	US	3	3	9	6	1	6	9	8/6/68	Daniel Lednicer	260	294.7	
	US	3	4	8	3	2	9	3	12/9/69	Gordon W. Duncan	424	274	
	US	3	5	6	7	7	3	7	3/2/71	Daniel Lednicer	37	00	
	US	3	8	6	2	2	3	2	1/21/75	Daniel Lednicer	260	570.7	
	US	4	1	3	3	8	1	4	1/9/79	C. David Jones	260	326.55	
	US	4	3	5	8	5	9	3	11/9/82	Jones, et al.	546	202	
	US	4	3	8	0	6	3	5	4/19/83	Mary K. Peters	546	202	
	US	4	4	1	8	0	6	8	11/29/83	Charles D. Jones	424	267	
	US	4	8	5	9	5	8	5	8/22/89	Sonnenschein et al.	435	29	
	US	5	0	4	7	4	3	1	9/10/91	Schickneder et al.	514	648	
	US	5	2	5	4	5	9	4	10/19/93	Niikura et al.	514	648	
	US	5	3	6	4	7	9	1	11/15/94	Vegeto et al.	435	320.1	
	US	5	3	8	4	3	3	2	1/24/95	Steven A. Fontana	514	648	
	US	5	3	8	9	6	7	0	2/14/95	Steven A. Fontana	514	443	
	US	5	3	9	1	5	5	7	2/21/95	Cullinan et al.	514	324	
	US	5	3	9	3	7	6	3	2/28/95	Black et al.	514	333	
	US	5	4	1	8	2	5	2	5/23/95	Daniel C. Williams	514	443	
	US	5	4	3	4	1	6	6	7/18/95	A.L. Glasebrook	514	317	
	US	5	4	3	9	9	2	3	8/8/95	George J. Cullinan	514	324	
	US	5	4	3	9	9	3	1	8/8/95	James J. Sales	514	443	
	US	5	4	4	1	9	6	6	8/15/95	Jeffrey A. Dodge	514	324	
	US	5	4	4	1	9	8	6	8/15/95	David D. Thompson	514	648	
ce	US	5	4	4	6	0	5	3	8/29/95	Patrick Keohane	514	324	

8-10-05



## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. PC9517H

SERIAL NO. 10/615,282

APPLICANT David B. MacLean, et al.


FILING DATE 7/7/2003

GROUP 1614

U	US	5	4	4	7	9	4	1	9/5/95	S.H. Zuckerman	514	324	
	US	5	4	5	1	5	8	9	9/19/95	Jeffrey A. Dodge	514	324	
	US	5	4	5	1	5	9	0	9/19/95	Jeffrey A. Dodge	514	324	
	US	5	4	5	5	2	7	5	10/3/95	Steven A. Fontana	514	648	
	US	5	4	5	7	1	1	3	10/10/95	Cullinan et al.	514	319	
	US	5	4	5	7	1	1	6	10/10/95	Black et al.	514	324	
	US	5	4	5	7	1	1	7	10/10/95	Black et al.	514	337	
	US	5	4	6	1	0	6	4	10/24/95	George J. Cullinan	514	324	
	US	5	4	6	1	0	6	5	10/24/95	Black et al.	514	324	
	US	5	4	6	2	9	3	7	10/31/95	Cullinan et al.	514	212	
	US	5	4	6	2	9	4	9	10/31/95	Jones et al.	514	324	
	US	5	4	6	2	9	5	0	10/31/95	Steven A. Fontana	514	324	
	US	5	4	5	4	8	4	5	11/7/95	Black et al.	514	326	
	US	5	4	7	0	8	5	4	11/28/95	Angerer, et al.	514	233.5	
	US	5	4	7	0	8	8	3	11/28/95	Brent V. Stromberg	514	648	
	US	5	4	8	2	9	4	9	1/9/96	Black, et al.	514	324	
	US	5	4	7	2	9	6	2	12/5/95	Koizumi, et al.	514	233.5	
	US	5	4	8	4	7	9	8	1/16/96	Bryant, et al.	514	324	
	US	5	5	1	0	3	5	7	4/23/96	Alan Palkowitz	514	324	
	US	5	5	3	2	3	8	2	7/2/96	Carlson, et al.	549	57	
	US	5	5	5	0	1	6	4	8/27/96	Steven A. Fontana	514	648	
	US	5	5	5	2	4	1	2	9/3/96	Cameron, et al.	514	317	
	US	5	5	6	7	8	2	8	10/22/96	Jeffrey A. Dodge	549	51	
	US	5	8	7	7	2	1	6	3/2/99	Place et al.	514	573	
	US	5	8	8	9	0	4	2	3/30/99	MacLean et al.	514	127	
	US	6	1	0	7	3	3	1	8/22/00	MacLean et al.	514	428	
	US	6	1	5	3	6	2	2	11/28/00	Cameron et al.	514	307	
	US	6	2	0	4	2	8	6	3/20/01	Cameron et al.	514	428	
U	US	6	2	4	5	8	1	9	6/12/01	Halonen et al.	514	721	

U - Ulelele


8-10-05



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)										ATTY. DOCKET NO. PC9517H		SERIAL NO.10/615,282		
										APPLICANT David B. MacLean, et al.				
										FILING DATE 7/7/2003		GROUP 1614		
EXAMINER INITIAL	US	6	4	0	3	6	1	1	6/11/02	MacLean et al.	514	315	FILING DATE IF APPROPRIATE	
DOCUMENT NUMBER														
FOREIGN PATENT DOCUMENTS														
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
16	EP	0	3	0	9	4	7	3	4/5/89	European	A61L	33/00		
1	EP	0	6	0	5	1	9	3	7/6/94	European	A61K	31/40		
	EP	0	6	1	7	0	3	0	9/28/94	European	Co7D	333/56		
	EP	0	6	3	5	2	6	4	1/25/95	European	A61K	31/38		
	EP	0	6	5	2	0	0	4	5/10/95	European	A61K	31/4465		
	EP	0	6	5	9	4	1	1	6/28/95	European	A61K	31/445		
	EP	0	6	5	9	4	1	3	6/28/95	European	A61K	31/445		
	EP	0	6	5	9	4	1	4	6/28/95	European	A61K	34/445		
	EP	0	6	5	9	4	1	5	6/28/95	European	A61K	31/445		
	EP	0	6	5	9	4	1	8	6/28/95	European	A61K	31/445		
	EP	0	6	5	9	4	1	9	6/28/95	European	A61K	31/445		
	EP	0	6	5	9	4	2	5	6/28/95	European	A61K	31/445		
	EP	0	6	5	9	4	2	7	6/28/95	European	A61K	31/445		
	EP	0	6	5	9	4	2	8	6/28/95	European	A61K	31/445		
	EP	0	6	5	9	4	2	9	6/28/95	European	A61K	31/445		
	EP	0	6	6	4	1	2	1	7/26/95	European	A61K	31/4535		
	EP	0	6	6	4	1	2	3	7/26/95	European	A61K	31/445		
	EP	0	6	6	4	1	2	5	7/26/95	European	A61K	31/445		
	EP	0	6	6	4	1	2	6	7/26/95	European	A61K	31/445		
	EP	0	7	9	2	6	4	0	09/03/97	European	A61K	31/135		
	EP	0	7	9	2	6	4	1	9/3/97	European	A61K	31/40		
	WO	9	3	0	7	1	4	9	4/15/93	International	C07D	487/04		
16	WO	9	5	1	0	5	1	3	4/20/95	International	C07D	333/56		


W. Ueda

8-10-00



800003  
INFORMATION DISCLOSURE CITATION LIST DOT 9/99



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC9517H		SERIAL NO.10/615,282		
		APPLICANT David B. MacLean, et al.				
		FILING DATE 7/7/2003		GROUP 1614		
ll			Endometriosis in the Rat", Volume 114 pages 379-382 (1987)			
			Osteoporosis Conference, SCRIP No. 1812/13, April 16 <sup>th</sup> /20 <sup>th</sup> pages 29-30 (1993)			
			Roland Loser et al., <u>Eur. J. Cancer Clin. Oncol.</u> , "In Vivo and In Vitro Antiestrogenic Action of 3-Hydroxytamoxifen, Tamoxifen and 4-Hydroxytamoxifen", Volume 21, No. 8, pages 985-990 (1985)			
ll			Urs Eppenberger et al., <u>Am. J. Clin. Oncol.</u> , "Pharmacologic and Biologic Properties of Droloxifene, A New Antiestrogen", Volume 14, Suppl. 2, S5-S14 (1991)			
EXAMINER  DATE CONSIDERED 8-10-03						
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE